3.5. VAFSD in ctDNA as a Biomarker for Atezolizumab Response
SOMATIC MUTATIONS
The ctDNA VAFSD of 53 ctDNA samples at C0 with two or more detected somatic mutations (bTMB ≥ 7.7 Mut/Mb) and 37 paired samples at C4/EOT was measured (At the cut-off value at C0 (0.014), there was no difference in the DCB rate (high 12.0% vs. low 21.4%; There was no difference in the PFS according to the VAFSD level at C0; however, the subgroup with no change or a decreased VAFSD level from C0 to C4/EOT had a longer PFS compared with the subgroup with an increased VAFSD level (